ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - ScPharmaceuticals reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -25.93% [1] - The company posted revenues of $11.75 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.67%, compared to revenues of $6.1 million a year ago [2] - Over the last four quarters, ScPharmaceuticals has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - ScPharmaceuticals shares have declined approximately 34.5% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $16.95 million, and for the current fiscal year, it is -$1.03 on revenues of $76.42 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ScPharmaceuticals belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ScPharmaceuticals' stock performance [5][6]